434.80
price up icon2.10%   8.95
pre-market  プレマーケット:  440.64   5.84   +1.34%
loading
前日終値:
$425.85
開ける:
$429.86
24時間の取引高:
265.11K
Relative Volume:
0.79
時価総額:
$9.87B
収益:
-
当期純損益:
$-518.67M
株価収益率:
-17.31
EPS:
-25.12
ネットキャッシュフロー:
$-438.32M
1週間 パフォーマンス:
-0.05%
1か月 パフォーマンス:
-9.15%
6か月 パフォーマンス:
+0.83%
1年 パフォーマンス:
+35.32%
1日の値動き範囲:
Value
$423.98
$443.61
1週間の範囲:
Value
$416.21
$448.13
52週間の値動き範囲:
Value
$265.00
$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name
名前
Madrigal Pharmaceuticals Inc
Name
セクター
Healthcare (1106)
Name
電話
404-380-9263
Name
住所
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Name
職員
528
Name
Twitter
@MadrigalPharma
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
MDGL's Discussions on Twitter

Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
MDGL
Madrigal Pharmaceuticals Inc
434.80 9.67B 0 -518.67M -438.32M -25.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.89 120.48B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
787.50 81.05B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
749.56 46.33B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.30 42.26B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.02 32.87B 5.36B 287.73M 924.18M 2.5229

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-28 開始されました Barclays Overweight
2026-01-06 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-05 アップグレード Cantor Fitzgerald Neutral → Overweight
2025-11-03 アップグレード BofA Securities Underperform → Neutral
2025-10-15 開始されました Truist Buy
2025-09-04 再開されました H.C. Wainwright Buy
2025-02-28 アップグレード B. Riley Securities Neutral → Buy
2025-02-27 繰り返されました H.C. Wainwright Buy
2024-06-28 開始されました Cantor Fitzgerald Neutral
2024-06-11 開始されました Wolfe Research Outperform
2024-04-22 開始されました BofA Securities Underperform
2024-03-15 アップグレード B. Riley Securities Sell → Neutral
2024-03-06 開始されました Citigroup Buy
2024-02-26 ダウングレード B. Riley Securities Neutral → Sell
2022-12-20 繰り返されました Oppenheimer Outperform
2022-12-19 繰り返されました H.C. Wainwright Buy
2022-12-19 繰り返されました Piper Sandler Overweight
2022-12-19 アップグレード Raymond James Underperform → Mkt Perform
2022-07-08 ダウングレード B. Riley Securities Buy → Neutral
2021-10-07 開始されました Jefferies Buy
2021-08-06 アップグレード BMO Capital Markets Market Perform → Outperform
2021-05-20 再開されました Goldman Buy
2020-11-24 再開されました Evercore ISI Outperform
2020-11-06 繰り返されました H.C. Wainwright Buy
2020-07-31 開始されました Piper Sandler Overweight
2020-06-05 開始されました BMO Capital Markets Market Perform
2020-05-05 開始されました Chardan Capital Markets Buy
2020-01-30 開始されました Canaccord Genuity Buy
2020-01-09 アップグレード UBS Neutral → Buy
2019-11-07 繰り返されました H.C. Wainwright Buy
2019-06-25 開始されました Stifel Hold
2019-06-10 アップグレード B. Riley FBR Neutral → Buy
2019-02-28 繰り返されました H.C. Wainwright Buy
2019-02-22 開始されました SVB Leerink Outperform
2019-01-23 開始されました UBS Neutral
2018-12-14 開始されました Wolfe Research Outperform
2018-12-12 開始されました B. Riley FBR Neutral
2018-11-19 ダウングレード Raymond James Mkt Perform → Underperform
2018-11-16 アップグレード Evercore ISI In-line → Outperform
2018-09-04 開始されました Citigroup Buy
2018-08-06 ダウングレード Goldman Buy → Neutral
2018-06-28 開始されました Raymond James Mkt Perform
すべてを表示

Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース

pulisher
06:27 AM

Segall Bryant & Hamill LLC Invests $10.32 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

06:27 AM
pulisher
01:39 AM

A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness - simplywall.st

01:39 AM
pulisher
Mar 04, 2026

Madrigal Pharmaceuticals: How Noninvasive Data Is Powering a Smarter Clinical Strategy! - Smartkarma

Mar 04, 2026
pulisher
Mar 04, 2026

Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by TD Asset Management Inc - MarketBeat

Mar 04, 2026
pulisher
Mar 03, 2026

MDGL: Rezdiffra's growth accelerates with a broad pipeline and strong 2026 financial outlook - TradingView

Mar 03, 2026
pulisher
Mar 03, 2026

Intech Investment Management LLC Lowers Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success - Finviz

Mar 03, 2026
pulisher
Mar 03, 2026

Madrigal Pharmaceuticals EVP Dier sells $505k in shares By Investing.com - Investing.com Canada

Mar 03, 2026
pulisher
Mar 02, 2026

Madrigal Pharmaceuticals (NASDAQ:MDGL) CFO Mardi Dier Sells 1,183 Shares - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

Madrigal Pharmaceuticals (MDGL) director sale notice: 1,183 shares after RSU vest - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

MADRIGAL PHARMACEUTICALS EVP and CFO Sells Shares to Cover Tax Obligations - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Madrigal (MDGL) CFO has shares sold automatically for tax withholding - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Exploring a 54% Upside Potential in the Biotech Sector - DirectorsTalk Interviews

Mar 02, 2026
pulisher
Mar 02, 2026

Rafferty Asset Management LLC Lowers Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

JPMorgan Chase & Co. Reduces Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 02, 2026
pulisher
Mar 01, 2026

William Blair Investment Management LLC Has $188.88 Million Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 01, 2026
pulisher
Feb 28, 2026

Artisan Partners Limited Partnership Acquires 4,683 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Feb 28, 2026
pulisher
Feb 26, 2026

Madrigal Q4 earnings miss, MASH drug sales drive top line, stock down - MSN

Feb 26, 2026
pulisher
Feb 26, 2026

MDGL SEC FilingsMadrigal Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan

Feb 26, 2026
pulisher
Feb 26, 2026

Fox Run Management L.L.C. Takes $1.06 Million Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Feb 26, 2026
pulisher
Feb 25, 2026

Why Madrigal Pharmaceuticals (MDGL) Is Down 9.7% After Rezdiffra’s Near US$1 Billion Debut Year - Yahoo Finance

Feb 25, 2026
pulisher
Feb 25, 2026

Exit Recap: Will Madrigal Pharmaceuticals Inc outperform during market ralliesEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn

Feb 25, 2026
pulisher
Feb 25, 2026

Madrigal: The Easiest Money May Have Been Made (NASDAQ:MDGL) - Seeking Alpha

Feb 25, 2026
pulisher
Feb 24, 2026

Director exercises 2,500 Madrigal (MDGL) options at $7.36 - Stock Titan

Feb 24, 2026
pulisher
Feb 24, 2026

Madrigal Pharmaceuticals Reports 2025 Financial Results - MyChesCo

Feb 24, 2026
pulisher
Feb 24, 2026

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times

Feb 24, 2026
pulisher
Feb 23, 2026

Madrigal Grants Inducement Awards to Five Employees - MyChesCo

Feb 23, 2026
pulisher
Feb 23, 2026

Madrigal (MDGL) Q4 2025 Earnings Call Transcript - The Globe and Mail

Feb 23, 2026
pulisher
Feb 23, 2026

A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s First Full Year Near US$1b In Sales - simplywall.st

Feb 23, 2026
pulisher
Feb 23, 2026

Madrigal Pharmaceuticals, Inc. (MDGL): Investor Outlook Reveals 53% Potential Upside In Biotechnology - DirectorsTalk Interviews

Feb 23, 2026
pulisher
Feb 23, 2026

Vanguard Group Inc. Sells 65,227 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Feb 23, 2026
pulisher
Feb 23, 2026

Madrigal’s Rezdiffra Breakthrough Spurs MASH Pipeline Growth And Valuation Debate - Yahoo Finance

Feb 23, 2026
pulisher
Feb 23, 2026

MASH Drugs Market to hit US$ 929.05 Million by 2033 | North America - openPR.com

Feb 23, 2026
pulisher
Feb 20, 2026

Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga

Feb 20, 2026
pulisher
Feb 20, 2026

Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down - Bitget

Feb 20, 2026
pulisher
Feb 20, 2026

Is now the right time to enter Madrigal Pharmaceuticals Inc.July 2025 Opening Moves & Safe Entry Momentum Tips - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

MDGL: B of A Securities Maintains Neutral Rating, Lowers Price T - GuruFocus

Feb 20, 2026
pulisher
Feb 20, 2026

Bank of America Issues Pessimistic Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price - MarketBeat

Feb 20, 2026
pulisher
Feb 20, 2026

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 20, 2026
pulisher
Feb 20, 2026

Fiera Capital Corp Lowers Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Feb 20, 2026
pulisher
Feb 20, 2026

Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN

Feb 20, 2026
pulisher
Feb 20, 2026

Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus

Feb 20, 2026
pulisher
Feb 19, 2026

Madrigal Pharma earnings missed by $1.97, revenue topped estimates - Investing.com Canada

Feb 19, 2026
pulisher
Feb 19, 2026

Madrigal Eyes MASH Future As Rezdiffra Nears Blockbuster Revenue - Citeline News & Insights

Feb 19, 2026
pulisher
Feb 19, 2026

Earnings call transcript: Madrigal Pharmaceuticals Q4 2025 misses EPS, stock dips - Investing.com India

Feb 19, 2026
pulisher
Feb 19, 2026

Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Highlights: Record Sales and ... By GuruFocus - Investing.com Canada

Feb 19, 2026
pulisher
Feb 19, 2026

Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Highli - GuruFocus

Feb 19, 2026
pulisher
Feb 19, 2026

Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Quarterly Earnings Results, Misses Estimates By $2.61 EPS - MarketBeat

Feb 19, 2026
pulisher
Feb 19, 2026

Madrigal Pharmaceuticals, Inc. reports strong Rezdiffra sales growth in Q4 2025; first full year of launch approaches $1 billion in net sales - AlphaStreet News

Feb 19, 2026
pulisher
Feb 19, 2026

Madrigal Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 19, 2026
pulisher
Feb 19, 2026

Madrigal Pharmaceuticals (MDGL) Reports Strong Q4 2025 Performan - GuruFocus

Feb 19, 2026

Madrigal Pharmaceuticals Inc (MDGL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$47.43
price down icon 0.11%
$29.52
price up icon 6.00%
$57.80
price up icon 15.99%
$103.80
price up icon 3.02%
$149.88
price up icon 1.96%
biotechnology ONC
$299.02
price up icon 0.67%
大文字化:     |  ボリューム (24 時間):